Details for Patent: 11,278,599

Which drugs does patent 11,278,599 protect, and when does it expire?

Patent 11,278,599 protects OPFOLDA and is included in one NDA.

This patent has eighteen patent family members in six countries.

Summary for Patent: 11,278,599

Patent landscape, scope, and claims:

Title:	High concentration alpha-glucosidase compositions for the treatment of Pompe disease
Abstract:	The present application provides for compositions comprising high concentrations of acid a-glucosidase in combination with an active site-specific chaperone for the acid α-glucosidase, and methods for treating Pompe disease in a subject in need thereof, that includes a method of administering to the subject such compositions. The present application also provides methods for increasing the in vitro and in vivo stability of an acid α-glucosidase enzyme formulation.
Inventor(s):	Kenneth Valenzano, John Crowley, Richie Khanna, John Flanagan
Assignee:	Amicus Therapeutics Inc
Application Number:	US16/580,541
Patent Claim Types: see list of patent claims

Drugs Protected by US Patent 11,278,599

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Amicus Therap Us	OPFOLDA	miglustat	CAPSULE;ORAL	215211-001	Sep 28, 2023		RX	Yes	Yes	11,278,599					THE TREATMENT OF POMPE PATIENTS

International Family Members for US Patent 11,278,599

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Canada	2866683
European Patent Office	2823043
Japan	2015509542
Japan	2018027945